RSV Burden in Hong Kong
ConditionRSV
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese University of Hong Kong
About this trial
RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest.
Eligibility criteria
Qualifiers
Community-acquired respiratory tract infection symptoms
Age >= 18
Disqualifiers
Unable to provide a good quality of sputum and saliva
Trial design
Treatments tested in this trial
- Serial specimen sampling
Treatment groups
10,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov